Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA

Inhibition of matrix metalloproteinases (MMPs) is an attractive approach to adjuvant therapy in the treatment of cancer. Marimastat is the first orally administered, synthetic MMP inhibitor to be evaluated, in this capacity, in the clinic. Measurement of the rate of change of circulating tumour anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, S A, Morris, T M, Collins, H M, Bawden, L J, Hawkins, K, Bone, E A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374341/
https://www.ncbi.nlm.nih.gov/pubmed/10487607
http://dx.doi.org/10.1038/sj.bjc.6690645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374341/
https://www.ncbi.nlm.nih.gov/pubmed/10487607
http://dx.doi.org/10.1038/sj.bjc.6690645

Ejemplares similares